Direct-to-Tumor Drug Delivery

Maximizing impact of the most effective cancer drugs while minimizing toxicity with a first-of-its-kind approach

Traditional Cancer Drug Delivery

Inefficient Systemic Delivery

0.01%

Only 1/10000th of the drug actually reaches the tumor

High Toxicity

The rest floods the body, causing severe side effects.
THE PROBLEM

Unmet Need

The Most Effective Cancer Drugs,

are the hardest to deliver to the tumor. NaDeNo solves this.

Critically Low Survival Rates

Advanced cancer patients face poor outcomes due to the lack of effective, tumor-targeted treatments.

NaDeNo’s Nanotechnology

Direct Tumor Targeting

NaDeNo’s nanoparticles encapsulate and protect FDA & EMA-approved drugs, ensuring direct, controlled release at the tumor site reducing systemic exposure and side effects.

Maximized Drug Efficacy

More of the drug reaches the tumor, boosting effectiveness while reducing toxicity, making chemotherapy safer and more powerful.
THE SOLUTION

Breakthrough in Cancer Care

Targets Hard-to-Treat Cancers

NaDeNo offers pharma and biotech companies technology to overcome drug delivery challenges for their most promising drugs.

97%

Tumor reduction in preclinical POC!

Engineered for Stability, Safety and Superior Drug Delivery

Differentiated for Impact

Scalability

High Tumor-Specific Efficacy

  • 97% tumor reduction in preclinical ovarian cancer models compared to free drug.
  • Significantly prolongs survival rates in preclinical cancer models.
Low-Cost Manufacturing

Dual-Action Mechanism

  • Tumor specific targeting without the need of targeting ligands.
  • Delivers drugs and modifies the tumor microenvironment to enhance immune responses.
Sustainability

Scalability

  • Sustainable, one-step, proprietary manufacturing enabling cost-effective, large-scale production.
  • Uniquely stable, homogenous formulations suitable for clinical and commercial use.

Additional Unique Properties and Benefits

  • Patented technology for encapsulating hydrophobic drugs without the need for chemical modification
  • Controlled drug release profile (30% burst, 40% over 8 hours, 30% over 2-4 weeks).
  • Built with FDA-approved materials (poly(alkyl cyanoacrylate)) to minimize regulatory hurdles.

  • Especially suited for local drug delivery for direct tumor targeting
  • Enhances drug accumulation at the tumor site while reducing off-target exposure

  • Using already approved active pharmaceutical ingredients with established safety and efficacy profiles
  • Recognized by NCI (National Cancer Institute) and backed by KOL (Key Opinion Leaders).
  • Aligned with regulatory bodies for smoother clinical translation.

  • Applicable across multiple hard-to-deliver hydrophobic drugs and challenging indications.
  • Customizable surface chemistry for tailored release rates and therapeutic needs.

  • Modifies the tumor microenvironment to suppress resistance and boost treatment efficacy.

  • Robust intellectual property with granted patents covering formulation, manufacturing, and applications.
  • 4 patent families
Round NanoParticle

How it works

Effective Drug Encapsulation

NaDeno’s nanoparticles securely encapsulate hard-to-deliver drugs, protecting them during delivery.
PACAB-002 Polymer Nanoparticle
PACAB-002 Polymer Nanoparticle
Encapsulated drug
Encapsulated drug – Patented nanoformulation of Cabazitaxel*
Ready-to-use Liquid Dispersion

Ready-to-use
Liquid Dispersion

Stable, homogenous formulation for precise and efficient dosing.

Targeted Delivery

Drugs are precisely delivered to tumors in the peritoneal cavity via a catheter, achieving high tumor concentrations through receptor-independent targeting
Targeted Delivery

Even Distribution & Long Retention Time

Even Distribution

The nanoparticles provide consistent drug delivery throughout the peritoneal cavity, reaching all tumor nodules

Long Retention:

The drug remains at therapeutic levels within the target area (peritoneum) for extended periods, unlike free drug or i.v. administration, which gives minimal local effectiveness.

Even Distribution & Long Retention Time

Safe Degradation

Nanoparticles break down into non-toxic components over time, leaving no harmful residues in the body.
Safe Degradation

  • PACAB-002 is our proprietary nanoformulation of Cabazitaxel encapsulated in polymeric nanoparticles.

  • An undisclosed oncology pipeline is advancing in collaboration with SINTEF.

  • We offer tailored nanoformulations to pharmaceutical and biotechnology companies in need of advanced solutions to overcome delivery hurdles of hydrophobic small molecule drugs.

Chart

Curious to see more detail?

Ask for the PACAB-002 Development Program and Route-to-Market!

Lead oncology candidate

PACAB-002

  • PACAB-002 are polymeric nanoparticles encapsulating cabazitaxel

  • Cabazitaxel is highly potent and has an established safety and efficacy profile

  • Preclinical data from various mouse cancer models show:

  • long drug retention time in the peritoneal cavity
  • tumor-specific accumulation
  • even distribution throughout the peritoneal cavity
  • significantly improved treatment effect and reduced side effects compared to free drug

Management Team

Management Team

Annbjørg Falck

Annbjørg Falck

Chief Executive Officer
and Co-founder
Bio
Yrr Mørch

Yrr Mørch

Chief Technology Officer
and Co-founder
Bio
Torgeir Vaage

Torgeir Vaage

Chief Financial Officer
Bio
Gudrun Trøite

Gudrun Trøite

Head of Operations
Bio

Partnerships

A few of our many
partners across:

Innovation & Testing

Organizations that contribute to preclinical research, early testing, and technology development.

Clinical Development

Renowned clinical institutions driving patient-focused trials to validate efficacy and safety in real-world settings.

Manufacturing & Supply Chain

Partners enabling production, scalability, and raw material sourcing.

Funding & Ecosystems

Organizations providing financial support, innovation clusters, and strategic networks

Regulatory & Intellectual Property

Experts in navigating regulatory approvals, patent protection, and compliance.

Partnership

We’re excited to announce our newest partnership with Phoenix

Insightful reads

Elesevier

What you’ll learn in this article:

  • PACA drug encapsulation improves treatment response in peritoneal metastases models.
  • Intraperitoneal injection of PACA nanoparticles provides a beneficial drug biodistribution.
  • Drug encapsulation in PACA nanoparticles improves intraperitoneal drug retention.
  • The taxane cabazitaxel is a promising chemotherapy option for peritoneal metastases.

Read the full article

Scitechnews

What you’ll learn in this article:

This article from Norwegian SciTech News will provide deeper understanding of NaDeNo’s innovative nanoparticle-based drug delivery system.

Read the full article